- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 5/00 - Drugs for disorders of the endocrine system
Patent holdings for IPC class A61P 5/00
Total number of patents in this class: 733
10-year publication summary
|
16
|
47
|
42
|
38
|
56
|
44
|
51
|
49
|
43
|
4
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Takeda Pharmaceutical Company Limited | 2713 |
11 |
| Albireo AB | 175 |
10 |
| Taisho Pharmaceutical Co., Ltd. | 863 |
10 |
| Novartis AG | 10463 |
9 |
| Amgen Inc. | 4301 |
7 |
| Banyu Pharmaceutical Co., Ltd. | 52 |
7 |
| MSD K.K. | 66 |
7 |
| Neurocrine Biosciences, Inc. | 430 |
7 |
| Spruce Biosciences, Inc. | 38 |
7 |
| F. Hoffmann-La Roche AG | 7875 |
6 |
| Genentech, Inc. | 4038 |
6 |
| Duke University | 3158 |
6 |
| The University of Queensland | 670 |
6 |
| Crinetics Pharmaceuticals, Inc. | 121 |
6 |
| Sanofi | 4159 |
6 |
| Daiichi Sankyo Company, Limited | 1875 |
5 |
| Eli Lilly and Company | 3964 |
5 |
| Sumitomo Dainippon Pharma Co., Ltd. | 211 |
5 |
| Mironid Limited | 23 |
5 |
| Société des Produits Nestlé S.A. | 9926 |
4 |
| Other owners | 598 |